92 related articles for article (PubMed ID: 7624152)
1. Viability of wild type p53-containing and p53-deficient tumor cells following anticancer treatment: the use of human papillomavirus E6 to target p53.
Labrecque S; Matlashewski GJ
Oncogene; 1995 Jul; 11(2):387-92. PubMed ID: 7624152
[TBL] [Abstract][Full Text] [Related]
2. Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation.
Thomas M; Matlashewski G; Pim D; Banks L
Oncogene; 1996 Jul; 13(2):265-73. PubMed ID: 8710365
[TBL] [Abstract][Full Text] [Related]
3. Induction of the p53-target gene GADD45 in HPV-positive cancer cells.
Butz K; Whitaker N; Denk C; Ullmann A; Geisen C; Hoppe-Seyler F
Oncogene; 1999 Apr; 18(14):2381-6. PubMed ID: 10327059
[TBL] [Abstract][Full Text] [Related]
4. Ceramide triggers p53-dependent apoptosis in genetically defined fibrosarcoma tumour cells.
Pruschy M; Resch H; Shi YQ; Aalame N; Glanzmann C; Bodis S
Br J Cancer; 1999 May; 80(5-6):693-8. PubMed ID: 10360645
[TBL] [Abstract][Full Text] [Related]
5. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line.
Wu GS; Ding Z
Oncogene; 2002 Jan; 21(1):1-8. PubMed ID: 11791171
[TBL] [Abstract][Full Text] [Related]
6. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage.
Smith ML; Chen IT; Zhan Q; O'Connor PM; Fornace AJ
Oncogene; 1995 Mar; 10(6):1053-9. PubMed ID: 7700629
[TBL] [Abstract][Full Text] [Related]
7. Human fibroblasts expressing the human papillomavirus E6 gene are deficient in global genomic nucleotide excision repair and sensitive to ultraviolet irradiation.
Ford JM; Baron EL; Hanawalt PC
Cancer Res; 1998 Feb; 58(4):599-603. PubMed ID: 9485006
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines.
Mantovani F; Banks L
Oncogene; 1999 Jun; 18(22):3309-15. PubMed ID: 10362351
[TBL] [Abstract][Full Text] [Related]
10. Down regulation of p53 with HPV E6 delays and modifies cell death in oxidant response of human diploid fibroblasts: an apoptosis-like cell death associated with mitosis.
Chen QM; Merrett JB; Dilley T; Purdom S
Oncogene; 2002 Aug; 21(34):5313-24. PubMed ID: 12149652
[TBL] [Abstract][Full Text] [Related]
11. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment.
Fan S; Cherney B; Reinhold W; Rucker K; O'Connor PM
Clin Cancer Res; 1998 Apr; 4(4):1047-54. PubMed ID: 9563901
[TBL] [Abstract][Full Text] [Related]
12. Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand.
Koivusalo R; Krausz E; Ruotsalainen P; Helenius H; Hietanen S
Cancer Res; 2002 Dec; 62(24):7364-71. PubMed ID: 12499281
[TBL] [Abstract][Full Text] [Related]
13. Abrogation of p53 function by transfection of HPV16 E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation.
Tsang NM; Nagasawa H; Li C; Little JB
Oncogene; 1995 Jun; 10(12):2403-8. PubMed ID: 7784090
[TBL] [Abstract][Full Text] [Related]
14. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth.
Pim D; Massimi P; Banks L
Oncogene; 1997 Jul; 15(3):257-64. PubMed ID: 9233760
[TBL] [Abstract][Full Text] [Related]
15. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline.
Fan S; Smith ML; Rivet DJ; Duba D; Zhan Q; Kohn KW; Fornace AJ; O'Connor PM
Cancer Res; 1995 Apr; 55(8):1649-54. PubMed ID: 7712469
[TBL] [Abstract][Full Text] [Related]
16. Elevated wild-type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene.
Demers GW; Halbert CL; Galloway DA
Virology; 1994 Jan; 198(1):169-74. PubMed ID: 8259651
[TBL] [Abstract][Full Text] [Related]
17. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells.
Yang B; Eshleman JR; Berger NA; Markowitz SD
Clin Cancer Res; 1996 Oct; 2(10):1649-57. PubMed ID: 9816112
[TBL] [Abstract][Full Text] [Related]
18. P53 plays a protective role against UV- and cisplatin-induced apoptosis in transcription-coupled repair proficient fibroblasts.
McKay BC; Becerril C; Ljungman M
Oncogene; 2001 Oct; 20(46):6805-8. PubMed ID: 11709715
[TBL] [Abstract][Full Text] [Related]
19. Transformed and tumor-derived human cells exhibit preferential sensitivity to the thiol antioxidants, N-acetyl cysteine and penicillamine.
Havre PA; O'Reilly S; McCormick JJ; Brash DE
Cancer Res; 2002 Mar; 62(5):1443-9. PubMed ID: 11888918
[TBL] [Abstract][Full Text] [Related]
20. Deregulated manganese superoxide dismutase expression and resistance to oxidative injury in p53-deficient cells.
Pani G; Bedogni B; Anzevino R; Colavitti R; Palazzotti B; Borrello S; Galeotti T
Cancer Res; 2000 Aug; 60(16):4654-60. PubMed ID: 10969820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
